Aducanumab: Promising Alzheimer’s drug or dangerous precedent?
The FDA has overruled the recommendations of its advisory panel, who were almost unanimously against approving the controversial drug.
Featured
Gene writing: The future of genetic medicine?
Tessera Therapeutics’ new technology could write therapeutic messages into genomes, treating genetic diseases at their source.
Bacterial “cell factories”: an eco-friendly approach to chemical production
Researchers at the University of Warwick have designed a genetic switch that reroutes bacteria’s chemistry to produce chemicals.
How is activity in the pharma sector recovering from Covid-19’s impact?
Analysis of jobs, deals, stock prices and financial filings and news sentiments now show pharma to be a relative winner when it comes to Covid-19 recovery.
Is the pharma sector seeing the beginnings of an AI investment boom?
AI deals, jobs and patents have been booming in the last few years. But is the pharma sector keeping up?
Alzheimer’s disease: how precision medicine could reverse cognitive decline
Alzheimer’s disease (AD), the most common form of dementia, affects over six million people in the US alone. By 2050, the number of people aged over 65 with the neurodegenerative…
Quantum Brilliance: reimagining drug discovery with quantum computing
The discovery and design of novel therapies is an increasingly challenging endeavour in the 21st century; though technology has progressed in leaps and bounds, identifying previously unknown molecules and drugs…
ARPA-H: Biden’s proposed government health agency hopes to cure cancer
In his first major address to Congress in April, US President Joe Biden announced an ambitious plan: to “end cancer as we know it”. The President has proposed a new…
PTF: Relinking the pharma supply chain
Pharma Technology Focus is now available on all devices. Read it for free here. The arrival of the Covid-19 pandemic threw a wrench into the everyday workings of the pharma supply…
Covid-19 vaccines: the role of social media in disinformation
Numerous conspiracy theories about the nature and origin of Covid-19 have circulated on the internet since the pandemic was declared last year, and have only been spurred on by the…
MorphoSys to acquire Constellation Pharmaceuticals for $1.7bn
MorphoSys has signed a definitive agreement to acquire Constellation Pharmaceuticals for a total equity value of $1.7bn or $34 per share, in cash. Constellation’s lead product candidates, pelabresib (CPI-0610), a…
